Diagnosis and cancer treatment company Avacta appeared today to curse Innova, which has received a lot of criticism recently ( ODX shares skyrocket as FDA asks Innova to stop selling COVID-19 testing Today, there is news that the lateral flow test has been registered by the EU.
Innova is the UK Government’s chosen supplier. rapid Immunochromatography-We have over £ 3 billion in contracts for tests conducted in China.
Immunochromatographic registration of the AffixDX SARS-CoV-2 antigen means that the product can be marketed in 27 EU countries, albeit for professional use.
CEO Alastair Smith seized the opportunity to emphasize the importance of testing thoroughly in the UK, emphasizing:
“This excellent performance and ease of nasal sampling, coupled with the fact that the AffiDX test has been performed. Developed in the UK,is Based on British technology And Manufactured in the UK, A big selling point for European customers. “
Popular stocks now have many commercial opportunities in the pipeline, adding that registration is the last step needed for the full commercialization of testing.
Omega Diagnostics also continued its gain train with a 5% rise early yesterday afternoon, while Avacta’s share surged more than 12% in response to the news.
Avacta curses Inova while firmly flying the British flag
Source link Avacta curses Inova while firmly flying the British flag